Victoza® (liraglutide) Received EU Marketing Authorization
Filed in archive Research , Treatment on July 6, 2009
Novo Nordisk's prime diabetes drug called Victoza® (liraglutide) has now received narketing authorization by the EU.
Victoza is the first once-daily human glucagon-like peptide-1 (GLP-1) analog developed for the treatment of type 2 diabetes and is now authorized in all 27 European Union member states for:
- combination treatment with metformin or a sulphonylurea in patients with insufficient glycemic control despite maximal tolerated dose of monotherapy with metformin or sulphonylurea, and
- combination treatment with metformin and a sulphonylurea or metformin and a thiazolidinedione in patients with insufficient glycemic control despite dual therapy.
Taken once daily,Victoza® is first human Glucagon-Like Peptide-1 (GLP-1) analogue. Find out more at Novo Nordisk.
Tags: diabetes diabetes Victoza liraglutide novo nordisk more liraglutide+received
Vote for Victoza® (liraglutide) Received EU Marketing Authorization:
|
Rating: 10.00 out of 4 vote(s) cast.
|
Response from:
keith
(11/30/09 9:33am)
i have been using victoza for one week and my glucose level have come right down and no side effect
Response from:
wouter
(03/21/10 1:10am)
I have been using victoza for 2 weeks now and my glucose level have come down, bur late n the afternoon the level is bey low(3.5). Some times I feel very dizzy andI am very fatique. But I think these side effects will dissapear.
| RSS |  |
 | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Follow us on Twitter! |
Most Popular
Best of
Blogs, Blogging & Blogosphere
Challenges
Developments
Diabetics' Device
Did you know
Diet
Education
Exercise
Family Matters
Friends
Fun
Information
Information about
Inspiration
Interviews
Lifestyle
Misc
News
Notable
